Cancer Diagnostics Market To Reach USD 247.1 Billion By 2027

Global Cancer Diagnostics Market: Key Highlights

According to the new market research report “Cancer Diagnostics Market by Type (Radiological Diagnostics, Cytological Diagnostics, Histological Diagnostics, Heamatogical Diagnostics, Immunohistochemistry, Molecular Diagnostics and Tumor Marker), by Cancer Type (Prostate Cancer, Brain Cancer, Ovarian Cancer, Breast Cancer, Skin Cancer, Bladder Cancer, Colorectal Cancer, Blood Cancer and Other Types of Cancer), by Region (North America, Asia Pacific, Europe, Middle East & Africa, South America) – Global Forecast (2020 to 2027)”, the global cancer diagnostics market is estimated to reach USD 247.1 Billion by 2027 at a CAGR of 7.2% during the review period.
Cancer is chronic, painful, sometimes progressive medical condition, an outcome of uncontrolled and abnormal cell growth leading to death
Cancer diagnostic is extremely important for early as well as accurate diagnosis of the disease for effective treatment
It can be termed as procedures used for accurate diagnosis of the cancer through examination of the tissue, cell, blood or body fluid sample

Cancer Diagnostics Market Global Cancer Diagnostics Market: Key Market Dynamics

Increased incidence of the cancer cases especially in the developed and developing economies is driving the market growth.
Higher demand for early cancer diagnosis for better treatment outcome, further fuels the market growth
High cancer treatment cost coupled with expensive diagnostic system and equipment acts as restraining factor for the cancer diagnostics market
Advancement in the technology with advent of advanced Diagnostic Test is acting as a growth opportunity for the cancer diagnostics market
Lack of skilled Professionals to perform diagnostic may challenge the market growth

Request Sample PDF Here: https://www.forencisresearch.com/cancer-diagnostics-market-sample-pdf/

Global Cancer Diagnostics Market: Regional Overview

North America

The cancer diagnostics market is dominated by the North America owing to rise in the prevalence of cancer across the region. The incidence of the cancer in the US is growing at a rapid rate. American Cancer Society revealed that 1.735 million new cancer cases were registered in 2018, 1.762 million new cases in 2019 and is expected to grow till 1.8 million in 2020. Rapid upsurge in the cancer patient pool, creates higher need for diagnostics devices in order to reduce the mortality rate and improve treatment outcomes. Increase funding for cancer research and cancer care, higher investment in boosting healthcare infrastructure in the region, further propels the market growth.

Asia-Pacific

The Asia-Pacific has emerged as the fastest growing region for cancer diagnostics market owing to presence of large patient pool. Increasing cancer incidence especially in Australia, China and South Asian countries with upsurge in the mortality rate of the cancer patient, requires higher attention towards boosting the cancer diagnostics and treatment. Changing lifestyles, growth in the middle class population, increasing count of smokers in the region, has triggered the cancer prevalence. Studies by the Johnson and Johnson company revealed that Asia Pacific accounts for half of the fresh cancer cases annually, where the death rate due to cancer in the region is projected to rise by 36% by 2030.

Global Cancer Diagnostics Market: Key Players Overview

F. Hoffmann-La Roche Ltd.:

F. Hoffmann-La Roche Ltd is a Switzerland based healthcare company. The company has strong foothold across North America, Latin America, Europe, Africa, Asia and Australia. The company operated through pharmaceutical division and diagnostic product portfolio. The company offers diagnostics solution dedicated for breast cancer, bladder cancer, cervical cancer, colorectal cancer, ovarian cancer and skin cancer. In January 2018, the company signed a partnership with the General Electric (US) for development of integrated digital diagnostics platform in order to enhance the oncology and critical care treatment.

BD:

Becton, Dickinson and Company abbreviated as BD, is a medical technology company based in United States. The company offers diverse product offering with the aim of maximize efficiency and flexibility of the treatment through molecular system, molecular test and molecular diagnostics. In December 2017, the company acquired C. R. Bard, Inc. a manufacturer of medical technologies with strong product portfolio and innovation pipeline for improving treatment and patient care by the healthcare service providers.

About Forencis Research

Forencis Research is a B2B market research, intelligence and advisory firm engaging in market research and consulting services across leading industries, globally. Our robust and meticulous research team provides high growth and niche syndicated reports, customized reports and consulting reports to the diverse global fortune clientele and intellectual institutions. Forencis Research database is a constantly evolving pool of market research reports and white paper studies which helps companies to foster accelerated revenue growth in global and regional markets.

Our robust research methodology is designed to constantly map the high growth markets in various industries. This facilitates enhanced decision-making capabilities to our clients. Our robust research methodology is designed to constantly map the high growth markets in various industries. This facilitates enhanced decision-making capabilities to our clients. We strive to help our clients to foray into uncharted space to attain increased revenue growth for the present as well as the future.

Contact Us:

FORENCIS RESEARCH

USA
Aurora
CO 80014

Phone: +1 (720) 306 9020

Email: sales@forencisresearch.com

Website: www.forencisresearch.com